Augmented Intelligence Company PercayAI Partners with Canopy Biosciences to Accelerate Drug Development

Canopy Biosciences, a leading provider of gene editing and gene expression products and services, to offer new service utilizing PercayAIโ€™s first commercial product, CompBioTM

PercayAI, a newly launched augmented intelligence software company that helps researchers develop new drugs more quickly and successfully, has announced its first strategic, commercial partnership with Canopy Biosciences.

Canopy Biosciences, a multi-omics service provider supporting leading labs at universities, biotechnology and pharmaceutical companies around the world, will offer PercayAIโ€™s CompBio coupled to their RNAseq and NanoString service. CompBio is software that quickly interprets data using a unique combination of artificial intelligence and contextual language processing to mimic the thought processes of biological science experts.

CompBio will complement Canopy Biosciences existing multi-omics platform and gene expression offerings by rapidly identifying non-obvious relationships within complex biological data sets. CompBio provides data in an intuitive, interactive 3D format that allows researchers to easily view all the information specific to their biological paradigm, helping scientists to have a greater understanding of the biology driving their research.

โ€œWith CompBio, researchers can explore the biological landscape and rapidly uncover insights in ways not possible with other tools,โ€ said Preston Keller, Ph.D., Director and Chief Commercial Officer of PercayAI. โ€œThrough our partnership with Canopy Biosciences, scientists will now have access to a powerful and innovative technological service that will help to improve the speed, cost and success rate of diagnostic and drug development.โ€

โ€œCanopy Biosciences licenses and provides the most ground-breaking technologies for researchers around the globe to advance the drug development process,โ€ said Edward Weinstein, Ph.D., CEO of Canopy Biosciences. โ€œOur collaboration with PercayAI will create a powerful union of genomics expertise with cutting-edge analysis solutions to best support scientists in drug development and lead to better patient outcomes.โ€

Mentioned in this Article

blank
Stories published by EQ Staff indicate that the article is based on a press release that's been sent to the editorial team via EQ's submit a press release for consideration form. Check the EQ IQ score on every article to determine how much due diligence took place. Press release submissions are not guaranteed placements and are selected for publishing on a merit basis. Feel free to drop us a line to learn more or if you have any questions.

Recent Posts

Pluton Biosciences and Bayer AG to Investigate Microbial-Based Carbon Capture

Pluton Biosciences Accepted into Plug and Play AgTech Accelerator

Popular Posts

How Arch Grantโ€™s Recipient Hemadvance Attracted its Startup Dream Team

Kingdom Capital Collaborates with Washington University School of Medicine to Launch Augmented Intelligence Company PercayAI

Can St. Louis Become the Next Bioscience Hub?

12 Fundraising Tips for BioTech Companies from Cultivation Capital’s Life Sciences Fund